Słowa kluczowe
terapia nowotworów
immunoterapia
Jak cytować
Abstrakt
Płaskonabłonkowy rak głowy i szyi (HNSCC, ang. Head and Neck Squamous Cell Carcinoma) to nowotwór wywodzący się z komórek płaskonabłonkowych błon śluzowych jamy ustnej, nosa lub gardła. Pomimo znacznych postępów konwencjonalnych metod leczenia, 5-letni wskaźnik przeżycia bez progresji u pacjentów z miejscowo zaawansowanym HNSCC HPV(-) nadal nie przekracza 50%. Niskie wskaźniki przeżycia w połączeniu z wysoką toksycznością stosowanych terapii, podkreślają konieczność wprowadzenia nowych strategii terapeutycznych. Obecne badania potwierdzają, że układ immunologiczny odgrywa kluczową rolę w patogenezie HNSCC. Lepsze zrozumienie mechanizmów molekularnych odpowiedzialnych za ucieczkę komórek nowotworowych spod kontroli układu immunologicznego oraz dokładne poznanie szlaków molekularnych odpowiedzialnych za rozwój płaskonabłonkowego raka głowy i szyi umożliwi opracowanie bardziej efektywnych terapii. Celem pracy jest przegląd wiedzy dotyczącej roli układu odpornościowego w ucieczce komórek nowotworowych HNSCC spod nadzoru immunologicznego.
Bibliografia
R. J. Sanderson i J. A. Ironside, “Squamous cell carcinomas of the head and neck,” BMJ, no. 325(7368): 822–827, 2002.
The Cancer Genome Atlas Network, “Comprehensive genomic characterization of head and neck squamous cell carcinomas,” Nature, vol. 517, no. 576–582, 2015.
Y. Suh, I. Amellio, T. Guerrero Urbano i M. Tavassoli, “Clinical update on cancer: molecular oncology of head,” Cell Death and Disease, 2014.
S. M. Thomas i J. R. Grandis, “The current state of head and neck cancer gene therapy.,” Human Gene Therapy, pp. 1565-1575, 2009.
L. Vidal i G. Maura, “Human Papillomavirus in HNSCC: Recognition of a Distinct Disease Type,” Hematology/Oncology Clinics of North America, pp. 1125-1142, 2008.
L. Licitra, G. Zigon, G. Gatta, M.-J. Sanchez, F. Berrino, “Human Papillomavirus in HNSCC: A European Epidemiologic Perspective,” Hematology/Oncology Clinics of North America, pp. 1143-1153, 2008.
J. M. Moskovitz i R. L. Ferris, “Tumor Immunology, Immunotherapy and Its Application to Head and Neck Squamous Cell Carcinoma (HNSCC),” Critical Issues in Head and Neck Oncology, no. 341-355, 2018.
J. D. Moy, J. M. Moskovitz, R. L. Ferris, “Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma,” European Journal of Cancer, pp. 152-166, 2017.
A. Jebreel, D. Mistry, D. Loke, “Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer.,” J Laryngol Otol, pp. 121:246-252, 2007.
N. M. Moutsopoulos, J. Wen, S. M. Wahl, “TGF-beta and tumors: An ill-fated alliance,” Curr Opin Immunol, pp. 20: 234-240, 2008.
Kuss, B. Hathaway, R. L. Ferris, W. Gooding, T. L. Whiteside, “Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck.,” Clinical cancer research, pp. 3755-3762, 2004.
T. Bauernhofer, I. Kuss, B. Henderson, . A. S. Baum, T. L. Whiteside, “Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer.,” European journal of immunology, pp. 119-124, 2003.
S. Dasgupta, M. Bhattacharya-Chatterjee, B. W. O’Malley, S. K. Chatterjee, “Inhibition of NK Cell Activity through TGF-β1 by Down-Regulation of NKG2D in a Murine Model of Head and Neck Cancer,” Journal of Immunology, pp. 5541-5550, 2005.
A. López-Albaitero, J. V. Nayak, T. Ogino, A. Machandia, W. Gooding, . A. B. DeLeo, S. Ferrone, R. L. Ferris, “Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL.,” Journal of Immunology, pp. 3402-3409, 2006.
R. L. Ferris, T. L. Whiteside, S. Ferrone, “Immune Escape Associated with Functional Defects in Antigen-Processing Machinery in Head and Neck Cancer,” Clin Cancer Res, pp. (13) 3890-3895, 2006
J. D. Schoenfeld, “ Immunity in head and neck cancer,” Cancer Immunol Res , pp. 12-17, 2015
M. Frisch , R. J. Biggar, E. A. Engels, J. J. Goedert, AIDS-Cancer Match Registry Study Group, “Association of cancer with AIDSrelated immunosuppression in adults.,” JAMA, pp. 285: 1736-1745, 2001.
A. E. Grulich, M. T. van Leeuwen, M. O. Falster, C. M. Vajdic , “Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis,” Lancet, pp. 370: 59-67, 2007.
S. A. Birkeland, H. H. Storm, L. U. Lamm, L. Barlow, I. Blohmé, B. Forsberg, B. Eklund, O. Fjeldborg, M. Friedberg, l. Frödin, “Cancer risk after renal transplantation in the Nordic countries, 1964-1986,” International Journal of Cancer, pp. 60:183-189, 1995.
V. Varilla , J. Atienza, C. A. Dasanu, “ Immune alterations and immunotherapy prospects in head and neck cancer.,” Expert Opin Biol Ther, pp. 1241-56, 2013.
R. D. Schreiber, L. J. Old, M. J. Smyth, “Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion,” Science, pp. 1565-1570, 2011.
F. Concha-Bravente, R. M. Srivastava, S. Trivedi, Y. Lei, U. Chandran, R. R. Seethala, “Identification of the cell intrinsic and -extrinsic pathways downstream of EGFR and IFNgamma that induce PD-L1 expression in head and neck cancer,” Cancer Res, pp. 1031-43, 2016.
M. Meissner, T. E. Reichert, M. Kunkel, W. Gooding, T. L. Whiteside, S. Ferrone, B. Seliger, “Defects in the Human Leukocyte Antigen Class I Antigen Processing Machinery in Head and Neck Squamous Cell Carcinoma: Association with Clinical Outcome,” Clinical Cancer Research, pp. 2552-60, 2005.
R. L. Ferris, “Immunology and Immunotherapy of Head and Neck Cancer,” Journal of Clinical Oncology, pp. 3293-3304, 2015.
The Cancer Genome Atlas Network, “Comprehensive genomic characterization of head and neck squamous cell carcinomas.,” Nature, pp. 517(7536):576-82, 2015.
A. López-Albaitero, . J. V. Nayak, T. Ogino, A. Machandia, W. Gooding, A. B. DeLeo, S. Ferrone, R. L. Ferris, “Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL.,” J Immunol , pp. 176 (6) 3402-3409, 2006.
C. Badoual, F. Sandoval, H. Pere, S. Hans, A. Gey, N. Merillon, C. Van Ryswick, F. Quintin‐Colonna, P. Bruneval , D. Brasnu, W. H. Fridman, E. Tartour, “Better understanding tumor–host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies,” Head & Neck, pp. 946-958, 2010.
M. S. Leibowitz, P. A. Filho, S. Ferrone, R. L. Ferris, “Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes.,” Cancer Immunol Immunother, pp. 525-535, 2016.
T. Ogino, H. Shigyo, H. Ishii, A. Katayama, N. Miyokawa, Y. Harabuchi, S. Ferrone, “HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker.,” Cancer Res, pp. (18) 9281-9289, 2006.
F. Concha-Benavente, R. M. Srivastava, S. Ferrone, R. L. Ferris, “EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3,” Oncoimmunology, p. 2(12):e27215, 2013.
M. S. Leibowitz, R. M. Srivastava, P. A. Andrade Filho, A. M. Egloff, L. Wang, R. R. Seethala, S. Ferrone, R. L. Ferris, “SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells,” Clin Cancer Res., pp. 19(4):798-808, 2013.
K. Mimura, K. Shiraishi,, A. Mueller,, S. Izawa,, L.-F. Kua, J. So, W.-P. Yong,, H. Fujii, B. Seliger, R. Kiessling, K. Kono, “The MAPK Pathway Is a Predominant Regulator of HLA-A Expression in Esophageal and Gastric Cancer,” The Journal of Immunology, p. 191(12): 6261–6272., 2013.
B. P. Pollack, B. Sapkota, T. V. Cartee, “Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes.,” Clin Cancer Res., pp. (13):4400-13, 2011.
R. M. Srivastava , S. Trivedi, F. Concha-Benavente , J. Hyun-Bae , L. Wang, R. R. Seethala, B. F. Branstetter, S. Ferrone, R. L. Ferris, “STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.,” Cancer Immunol Res., pp. (8) 936-45, 2015.
S. Trivedi, F. Concha-Benavente, R. M. Srivastava, H. B. Jie, S. P. Gibson, N. C. Schmitt, R. L. Ferris, “Immune biomarkers of anti-EGFR monoclonal antibody therapy,” Annals of Oncology, pp. 40-47, 2015.
E. V. Fletcher , L. Love-Homan, A. Sobhakumari , C. R. Feddersen , A. T. Koch, A. Goel, A. L. Simons, “EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.,” Molecular Cancer Research, pp. (12):1574-84, 2013.
H. von Boehmer i F. Melchers, “Checkpoints in lymphocyte development and autoimmune disease,” Nature Immunology, pp. 14-20, 2010.
K. C. Ohaegbulam, A. Assal, E. Lazar-Molnar, Y. Yao, X. Zang, “Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway,” Trends in Molecular Medicine, pp. 24-33, 2015.
C. Camisaschi, A. De Filippo, V. Beretta, B. Vergani, A. Villa, E. Vergani, “Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3,” Journal of Investigative Dermatology, pp. 1893-1902, 2014.
K. Sakuishi, L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo, A. C. Anderson, “Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity,” JEM, p. (10): 2187, 2010.
R. Mandal, Y. Senbabaoglu, A. Desrichard, J. J. Havel, M. G. Dalin, N. Riaz, “The head and neck cancer immune landscape and its immunotherapeuticimplications,” JCI Insight, p. 1:e89829.doi:10.1172/jci.insight. 89829, 2016.
P. Baruah, M. Lee, T. Odutoye, P. Williamson, N. Hyde, J. C. Kaski, I. E. Dumitriu, “Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients.,” Immunobiology, p. 217(7):669–75, 2012.